AbCellera Biologics
ABCL
9.69
-0.78
-7.45%
AbCellera Biologics
US · ABCL
#2215 by market cap
Listed 2020
9.69
-0.78
-7.45%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
About AbCellera Biologics
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
- Founded
- 2012
- CEO
- Dr. Carl L.G. Hansen, PhD
- Employees
- 562
- Headquarters
- Vancouver, British Columbia, Canada
- Fiscal year end
- 12-31
- Website
- abcellera.com
Company profile
- Exchange
- US
- Symbol
- ABCL
- Market-cap rank
- #2215
- Listing date
- 2020-12-11
- Market cap
- 3.16B
- Float cap
- 2.17B
- Shares out
- 326.62M
- Float shares
- 224.45M
Sectors & themes
Quote time 2026-11-20 19:59:30 · For reference only, not investment advice and not tailored to your situation.
AbCellera Biologics discussion 0 comments